McKesson - MCK STOCK NEWS

McKesson (NYSE: MCK) has announced a definitive agreement to acquire an 80% controlling interest in PRISM Vision Holdings for approximately $850 million. PRISM Vision physicians will retain the remaining 20% interest. PRISM Vision is a premier provider of general ophthalmology and retina management services, operating with more than 180 providers across 91 office locations and seven ambulatory surgery centers.

The acquisition will be consolidated within McKesson's U.S. Pharmaceutical segment and is expected to be $0.20 to $0.30 accretive to McKesson's Adjusted Earnings Per Diluted Share in the first 12 months, growing to $0.65 to $0.75 by the end of the third year. The transaction aims to strengthen McKesson's position in retina and ophthalmology care, expand data and analytics capabilities, and enhance clinical research opportunities.

McKesson (NYSE:MCK) has announced its Board of Directors has declared a quarterly dividend of $0.71 per share of common stock. The dividend will be distributed to shareholders of record as of March 3, 2025, with the payment scheduled for April 1, 2025.

McKesson (NYSE: MCK) has successfully completed the divestiture of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm, on December 30, 2024. The transaction, which was initially announced in September 2024, aligns with McKesson's strategic focus on capital deployment and prioritization of investments in expanding its oncology and biopharma growth platforms.

McKesson (NYSE: MCK) will release its third quarter fiscal 2025 financial results after market close on Wednesday, February 5, 2025. The company will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time to review its financial results. Chief Executive Officer Brian Tyler and Chief Financial Officer Britt Vitalone will be participating in the 43rd Annual J.P. Morgan Healthcare Conference on Tuesday, January 14, 2025. The live webcast for each event will be available on McKesson’s Investor Relations website at http://investor.mckesson.com, along with the company’s earnings release, financial tables and slide presentation.

McKesson has announced its fiscal 2025 second quarter financial results. The detailed results are accessible on McKesson’s Investor Relations website. Additionally, the company has raised its full-year adjusted EPS guidance.

McKesson will host a live webcast of the earnings conference call on Wednesday, November 6th at 4:30 PM ET. The webcast and related materials, including the press release, financial tables, and slide presentation, will be available on McKesson's Investor Relations website. Further information about upcoming investor events is also available on the same site.

McKesson (NYSE:MCK) announced that its Board of Directors has declared a regular quarterly dividend of $0.71 per share of common stock. The dividend will be distributed to shareholders of record as of December 2, 2024, with the payment scheduled for January 2, 2025.

McKesson (NYSE: MCK) has announced the release date for its second quarter fiscal 2025 financial results. The company will unveil its earnings after market close on Wednesday, November 6, 2024. Following the release, McKesson will host a live webcast of the earnings conference call for investors at 4:30 PM Eastern Time.

Investors can access the live webcast on McKesson's Investor Relations website at http://investor.mckesson.com. The website will also provide access to the company's earnings release, financial tables, and slide presentation. This announcement allows shareholders and interested parties to mark their calendars for McKesson's upcoming financial disclosure and discussion of its quarterly performance.

McKesson (NYSE: MCK) has announced the sale of its Canada-based Rexall and Well.ca businesses to Birch Hill Equity Partners, a Canadian private equity firm. This strategic move aligns with McKesson's enterprise strategy to focus on growing its oncology and biopharma services platforms. The transaction allows McKesson to streamline its business and prioritize investments in key growth areas.

Despite this divestiture, McKesson remains committed to its Canadian distribution and biopharma businesses. The company believes that Rexall and Well.ca will benefit from Birch Hill's resources and capital to expand their services across Canada. McKesson Canada intends to continue as a wholesale distribution supplier to both businesses after the transaction closes.

McKesson (NYSE: MCK) has announced a definitive agreement to acquire a controlling interest in Community Oncology Revitalization Enterprise Ventures, (Core Ventures) for approximately $2.49 billion in cash. This acquisition will give McKesson about 70% ownership of Core Ventures, a business and administrative services organization established by Florida Cancer Specialists & Research Institute (FCS).

Following the transaction, FCS will join The US Oncology Network, part of McKesson's Oncology platform. FCS, with over 250 physicians and 280 advanced practice providers across nearly 100 locations in Florida, will remain independently owned. This strategic move aims to enhance McKesson's integrated oncology platform and advance community-based oncology care.